Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
Arcellx (NASDAQ: ACLX) has appointed Andrew Galligan and Kristin Myers to its Board of Directors, while Derek Yoon steps down. The appointments come as the company prepares for potential commercialization in 2026.
Galligan, former CFO of Nevro Corp, brings over 30 years of strategic leadership experience, having driven commercial growth at multiple public companies. Myers, currently COO at Blue Cross Blue Shield Association, contributes 20+ years of healthcare expertise across payer, provider, and medtech sectors.
The appointments align with Arcellx's preparation for the anticipated commercial launch of anito-cel, their lead product candidate for relapsed or refractory multiple myeloma, through their partnership with Kite, a Gilead Company.
Arcellx (NASDAQ: ACLX) ha nominato Andrew Galligan e Kristin Myers nel suo Consiglio di Amministrazione, mentre Derek Yoon si dimette. Le nuove nomine arrivano mentre l'azienda si prepara per una potenziale commercializzazione nel 2026.
Galligan, ex CFO di Nevro Corp, porta con sé oltre 30 anni di esperienza nella leadership strategica, avendo guidato la crescita commerciale in diverse aziende pubbliche. Myers, attualmente COO presso la Blue Cross Blue Shield Association, contribuisce con oltre 20 anni di esperienza nel settore sanitario, coprendo i settori dei pagatori, dei fornitori e della tecnologia medica.
Le nomine sono in linea con la preparazione di Arcellx per il lancio commerciale previsto di anito-cel, il loro principale candidato prodotto per il mieloma multiplo recidivante o refrattario, attraverso la loro partnership con Kite, una società di Gilead.
Arcellx (NASDAQ: ACLX) ha nombrado a Andrew Galligan y Kristin Myers en su Junta Directiva, mientras que Derek Yoon renuncia. Los nombramientos se producen mientras la empresa se prepara para una posible comercialización en 2026.
Galligan, ex CFO de Nevro Corp, aporta más de 30 años de experiencia en liderazgo estratégico, habiendo impulsado el crecimiento comercial en múltiples empresas públicas. Myers, actual COO de la Asociación Blue Cross Blue Shield, contribuye con más de 20 años de experiencia en el sector de la salud, abarcando los sectores de pagadores, proveedores y tecnología médica.
Los nombramientos están alineados con la preparación de Arcellx para el lanzamiento comercial anticipado de anito-cel, su principal candidato a producto para el mieloma múltiple recaído o refractario, a través de su asociación con Kite, una empresa de Gilead.
Arcellx (NASDAQ: ACLX)는 Andrew Galligan과 Kristin Myers를 이사회의 임원으로 임명하고, Derek Yoon은 사임했습니다. 이러한 임명은 회사가 2026년 상업화를 준비하는 과정에서 이루어졌습니다.
Galligan은 Nevro Corp의 전 CFO로서 30년 이상의 전략적 리더십 경험을 가지고 있으며, 여러 상장 기업에서 상업적 성장을 이끌어 왔습니다. Myers는 현재 Blue Cross Blue Shield Association의 COO로서, 지불자, 제공자 및 의료 기술 분야에서 20년 이상의 헬스케어 전문성을 기여하고 있습니다.
이러한 임명은 Arcellx가 Kite(길리아드 회사)와의 파트너십을 통해 재발성 또는 난치성 다발성 골수종을 위한 주요 제품 후보인 anito-cel의 상업적 출시를 준비하는 것과 일치합니다.
Arcellx (NASDAQ: ACLX) a nommé Andrew Galligan et Kristin Myers au sein de son Conseil d'Administration, tandis que Derek Yoon démissionne. Ces nominations interviennent alors que l'entreprise se prépare à une éventuelle commercialisation en 2026.
Galligan, ancien CFO de Nevro Corp, apporte plus de 30 ans d'expérience en leadership stratégique, ayant conduit la croissance commerciale dans plusieurs entreprises publiques. Myers, actuellement COO de l'Association Blue Cross Blue Shield, contribue avec plus de 20 ans d'expertise dans le secteur de la santé, couvrant les secteurs des payeurs, des fournisseurs et de la technologie médicale.
Les nominations s'inscrivent dans la préparation d'Arcellx pour le lancement commercial anticipé de anito-cel, leur principal candidat produit pour le myélome multiple récurrent ou réfractaire, grâce à leur partenariat avec Kite, une entreprise de Gilead.
Arcellx (NASDAQ: ACLX) hat Andrew Galligan und Kristin Myers in seinen Vorstand berufen, während Derek Yoon zurücktritt. Die Ernennungen erfolgen, während das Unternehmen sich auf eine potenzielle Kommerzialisierung im Jahr 2026 vorbereitet.
Galligan, ehemaliger CFO von Nevro Corp, bringt über 30 Jahre Erfahrung in strategischer Führung mit, während er das kommerzielle Wachstum in mehreren börsennotierten Unternehmen vorangetrieben hat. Myers, derzeit COO der Blue Cross Blue Shield Association, bringt über 20 Jahre Erfahrung im Gesundheitswesen aus den Bereichen Zahler, Anbieter und Medizintechnologie mit.
Die Ernennungen stehen im Einklang mit der Vorbereitung von Arcellx auf den bevorstehenden kommerziellen Launch von anito-cel, ihrem Hauptproduktkandidaten für rezidiviertes oder refraktäres multiples Myelom, durch ihre Partnerschaft mit Kite, einem Unternehmen von Gilead.
- Strategic board appointments strengthen commercial expertise ahead of planned 2026 product launch
- Partnership with Kite (Gilead) in place for anito-cel commercialization
- Lead candidate anito-cel showing promising clinical profile in multiple myeloma
- None.
-- Mr. Galligan and Ms. Myers bring decades of experience to the company board --
-- Derek Yoon steps down from the Board of Directors --
“On the heels of our significant business progress in 2024, we are excited to welcome both Andrew and Kristin to the Arcellx Board of Directors as we continue to accelerate our development pipeline and organizational growth,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “As we take steps toward becoming a commercial-stage company in 2026, their deep knowledge and experience in commercial strategies and operations will complement the robust experience with our existing Board members. Notably, Andrew has been instrumental in building the financial and operational infrastructure to support commercial initiation and growth at multiple public companies. Kristin’s background and executive leadership expertise in the healthcare sector will be invaluable in guiding our market access strategies and patient and physician outreach initiatives.”
Mr. Elghandour added, “As Andrew and Kristin join other members of our distinguished Board of Directors, I would like to thank Derek Yoon for his contributions to our Board. From the earliest stages of our company, his trusted guidance has been instrumental to our growth and success.”
Most recently, Mr. Galligan served as Chief Financial Officer at Nevro Corp., a medical device company in the implantable spinal cord stimulation market. During his 10-year tenure at Nevro, he built the finance and operations group from commercial launch and drove year-over-year revenue growth. Prior to that, he was Vice President, Finance and Chief Financial Officer at Ooma, Inc., where he currently serves as a Board Member. Before that, he served in the same executive capacity at Reliant Technologies, Inc. and helped complete the acquisition of the company by Thermage, Inc. Mr. Galligan’s biotechnology industry executive experience also includes senior financial leadership roles at Metrika Inc. (acquired by Bayer), Corcept Therapeutics Incorporated, and Amira Medical (acquired by Roche). He holds a Business Studies degree from Trinity College,
“With its lead product candidate, anito-cel, demonstrating meaningful potential in the treatment of relapsed or refractory multiple myeloma, Arcellx is well positioned to address the need for a new treatment option that can make a difference in the lives of patients and their families,” said Mr. Galligan. “As the company prepares for the anticipated commercial launch of anito-cel in 2026, I am pleased to support the Arcellx team in this critical endeavor in my new role as a Board member.”
Ms. Myers brings 20+ years of healthcare experience, including senior leadership roles across the payer, provider and medtech sectors. Currently, she serves as the Chief Operating Officer at Blue Cross Blue Shield Association, leading strategic, operational and technology teams to support the BCBS System. Prior to this, Ms. Myers founded and led Hopscotch Primary Care as the CEO, standing up primary care centers to serve vulnerable patient populations across rural America. Previously, Ms. Myers held several positions of increasing responsibility at Aetna, beginning as Chief of Staff to the CEO and Chairman, and eventually rising to President of the Great Lakes Region. Ms. Myers’ career also included time in venture capital investing in the healthcare and biotech sectors. She holds an MBA from Harvard Business School and a BS in Biomedical Engineering from the University of
“The differentiated clinical profile of anito-cel, which is supported by late-stage studies, underscores Arcellx’s potential to change the treatment paradigm in multiple myeloma,” said Ms. Myers. “I look forward to supporting Arcellx’s experienced executive team as it moves closer to the market launch of anito-cel through its partnership with Kite, a Gilead Company.”
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X @arcellx and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding: the potential of anito-cel for providing meaningful benefit in patients suffering from multiple myeloma and to change the treatment paradigm in multiple myeloma; the potential impact of anito-cel on rrMM patients and expected clinical profile; anito-cel tolerability and toxicity trends; the potential commercial launch of anito-cel in 2026, subject to FDA approval, in partnership with Kite; Arcellx’s ability to deliver cell therapies that will meet the key expectations of patients and clinicians and serve the multiple myeloma community; trends relating to Arcellx’s development pipeline and organizational growth. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and the other documents that Arcellx may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320576099/en/
Investor Contact:
Myesha Lacy
Arcellx, Inc.
ir@arcellx.com
510-418-2412
Media Contact:
Andrea Cohen
Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
Source: Arcellx, Inc.
FAQ
When is Arcellx (ACLX) planning to launch anito-cel commercially?
What is the target indication for Arcellx's (ACLX) lead product anito-cel?
Who are the new Board members appointed to Arcellx (ACLX)?
Which company is partnering with Arcellx (ACLX) for anito-cel's commercialization?
